Hovione has acquired start-up company, ExtremoChem, expanding its technology platforms. Specialist integrated contract development and manufacturing organization (CDMO), Hovione, has acquired ExtremoChem, which is a start-up company with a portfolio of rare sugars, expanding its technology platforms. According to a Nov. 16, 2023 press release, the acquisition gives Hovione access
UK industry body, ABPI, has responded positively to the recent Autumn Statement. The United Kingdom’s industry body, the Association of the British Pharmaceutical Industry (ABPI), has reacted positively to the Autumn Statement from the government’s Chancellor, Jeremy Hunt. In his Autumn Statement, Hunt outlined the government’s plans
Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders. On Nov. 14, 2023 Autifony Therapeutics Limited announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals to discover and develop drug candidates targeting two ion channels
Twist Bioscience now offers its Express Genes rapid gene synthesis service at its Wilsonville, Ore. manufacturing facility. Twist Bioscience, a synthetic biology and genomics company, announced on Nov. 14, 2023 that it has launched Express Genes, a new gene synthesis service with a quick turnaround time of five to seven
The 3M Harvest RC Chromatographic Clarifier, BT500 is the latest addition to the company’s chromatographic clarifier portfolio. On Nov. 15, 2023, 3M announced the latest addition to its chromatographic clarifier portfolio. The Harvest RC Chromatographic Clarifier, BT500 is a 500-mL size, single-use chromatographic clarifier for monoclonal antibodies, recombinant proteins,
Lonza’s new GS Effex cell line can help overcome the challenges of developing therapeutic antibodies with increased potency. On Nov. 14, 2023, Lonza announced the launch of its new cell line, GS Effex, which is intended for the development of therapeutic antibodies with enhanced potency. Derived from the company’
Adzynma provides a replacement for low levels of the ADAMTS13 enzyme in patients with congenital thrombotic thrombocytopenic purpura. On November 9, 2023, FDA announced the approval of Adzynma, the first genetically engineered protein product for preventative or on-demand enzyme replacement therapy (ERT) for adult and pediatric patients with congenital thrombotic
Aitia will access Charles River’s Logica drug solution platform to develop therapeutic programs for neurodegenerative disease and oncology. Aitia, a drug development and drug discovery technology company, announced on Nov. 13, 2023 a partnership with Charles River Laboratories, a contract development and manufacturing organization. Under the partnership, Aitia will